Fig. 6

Effect of vistusertib in combination with neratinib/fulvestrant in cell line models of endocrine- and palbociclib-resistant BC. a Effect of escalating doses of vistusertib in combination with fulvestrant (1 nM) (Fulv) and neratinib (500 nM) on proliferation of MCF7 LTED^wt cell lines in the presence of 0.01 nM E2. Data are expressed as the percentage of viable cells relative to vehicle control. b Effect of escalating doses of vistusertib with or without fulvestrant (1 nM) on proliferation of palbociclib-resistant MCF7^PalboR, MCF7 LTED^PalboR and T47D^PalboR cell lines. Data are expressed as luminescence. Error bars represent mean ± SEM